Patents by Inventor Daniel Groff

Daniel Groff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • strains for producing full-length antibodies
    Patent number: 12673983
    Abstract: This disclosure provides methods and compositions related to producing full-length antibodies in E. coli having an oxidative cytoplasm, which is helpful for maintaining the three-dimensional structure and stability of proteins having disulfide bonds. The E. coli is used to produce full length antibody in high yield.
    Type: Grant
    Filed: June 6, 2025
    Date of Patent: July 7, 2026
    Assignee: Sutro Biopharma. Inc.
    Inventors: Daniel Groff, Jeffrey Hanson
  • E. COLI STRAINS HAVING AN OXIDATIVE CYTOPLASM
    Publication number: 20260078337
    Abstract: This disclosure provides an E. coli strain, which lacks thioredoxin reductase activity encoded by trxB and thioredoxin 1 activity encoded by trxA, and glutathione reductase activity encoded by gor. Said E. coli strain expresses a mutated AhpC protein having glutathione reductase activity and a cytosolic prokaryotic disulfide isomerase. The E. coli strain has an oxidative cytosol and can be used to efficiently produce proteins having disulfide bonds.
    Type: Application
    Filed: August 8, 2025
    Publication date: March 19, 2026
    Inventor: Daniel Groff
  • strains having an oxidative cytoplasm
    Patent number: 12410393
    Abstract: This disclosure provides an E. coli strain, which lacks thioredoxin reductase activity encoded by trxB and thioredoxin 1 activity encoded by trxA, and glutathione reductase activity encoded by gor. Said E. coli strain expresses a mutated AhpC protein having glutathione reductase activity and a cytosolic prokaryotic disulfide isomerase. The E. coli strain has an oxidative cytosol and can be used to efficiently produce proteins having disulfide bonds.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: September 9, 2025
    Assignee: Sutro Biopharma, Inc.
    Inventor: Daniel Groff
  • Methods of producing full-length antibodies using
    Patent number: 12351850
    Abstract: This disclosure provides a method of producing full-length antibodies in E. coli with a yield of at least about 200 mg/L. The E. coli cells typically have an oxidative cytoplasm, which is helpful for maintaining the three-dimensional structure and stability of proteins having disulfide bonds. In some cases, the molar ratio of the produced HC and LC amount from culturing the E. coli ranges from about 1:1 to about 1:3 (e.g., from about 1:1 to about 1:2.5, from about 1:1 to about 1:2).
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: July 8, 2025
    Assignee: Sutro Biopharma, Inc.
    Inventors: Daniel Groff, Jeffrey Hanson
  • E. COLI STRAINS HAVING AN OXIDATIVE CYTOPLASM
    Publication number: 20230002722
    Abstract: This disclosure provides an E. coli strain, which lacks thioredoxin reductase activity encoded by trxB and thioredoxin 1 activity encoded by trxA, and glutathione reductase activity encoded by gor. Said E. coli strain expresses a mutated AhpC protein having glutathione reductase activity and a cytosolic prokaryotic disulfide isomerase. The E. coli strain has an oxidative cytosol and can be used to efficiently produce proteins having disulfide bonds.
    Type: Application
    Filed: June 29, 2022
    Publication date: January 5, 2023
    Inventor: Daniel Groff
  • strains having an oxidative cytoplasm
    Patent number: 11407975
    Abstract: This disclosure provides an E. coli strain, which lacks thioredoxin reductase activity encoded by trxB and thioredoxin 1 activity encoded by trxA, and glutathione reductase activity encoded by gor. Said E. coli strain expresses a mutated AhpC protein having glutathione reductase activity and a cytosolic prokaryotic disulfide isomerase. The E. coli strain has an oxidative cytosol and can be used to efficiently produce proteins having disulfide bonds.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: August 9, 2022
    Assignee: Sutro Biopharma, Inc.
    Inventor: Daniel Groff
  • E. COLI STRAINS HAVING AN OXIDATIVE CYTOPLASM
    Publication number: 20210348118
    Abstract: This disclosure provides an E. coli strain, which lacks thioredoxin reductase activity encoded by trxB and thioredoxin 1 activity encoded by trxA, and glutathione reductase activity encoded by gor. Said E. coli strain expresses a mutated AhpC protein having glutathione reductase activity and a cytosolic prokaryotic disulfide isomerase. The E. coli strain has an oxidative cytosol and can be used to efficiently produce proteins having disulfide bonds.
    Type: Application
    Filed: November 7, 2019
    Publication date: November 11, 2021
    Inventor: Daniel Groff
  • Methods of Producing Full-Length Antibodies Using E. coli
    Publication number: 20210340586
    Abstract: This disclosure provides a method of producing full-length antibodies in E. coli with a yield of at least about 200 mg/L. The E. coli cells typically have an oxidative cytoplasm, which is helpful for maintaining the three-dimensional structure and stability of proteins having disulfide bonds. In some cases, the molar ratio of the produced HC and LC amount from culturing the E. coli ranges from about 1:1 to about 1:3 (e.g., from about 1:1 to about 1:2.5, from about 1:1 to about 1:2).
    Type: Application
    Filed: April 29, 2021
    Publication date: November 4, 2021
    Inventors: Daniel Groff, Jeffrey Hanson